These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 21718264)

  • 1. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events?
    Paquette A; Gou P; Tannenbaum C
    J Am Geriatr Soc; 2011 Jul; 59(7):1332-9. PubMed ID: 21718264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
    Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG
    Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.
    Chapple CR; Khullar V; Gabriel Z; Muston D; Bitoun CE; Weinstein D
    Eur Urol; 2008 Sep; 54(3):543-62. PubMed ID: 18599186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
    Wagg A; Compion G; Fahey A; Siddiqui E
    BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Antimuscarinic Drugs on Cognitive Functions in the Management of Overactive Bladder in Elderly.
    Rangganata E; Widia F; Rahardjo HE
    Acta Med Indones; 2020 Jul; 52(3):255-263. PubMed ID: 33020336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder.
    Yamada S; Ito Y; Nishijima S; Kadekawa K; Sugaya K
    Pharmacol Ther; 2018 Sep; 189():130-148. PubMed ID: 29709423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of neurocognitive dysfunction with overactive bladder medications.
    Duong V; Iwamoto A; Pennycuff J; Kudish B; Iglesia C
    Int Urogynecol J; 2021 Oct; 32(10):2693-2702. PubMed ID: 34213600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin.
    Kay GG; Ebinger U
    Int J Clin Pract; 2008 Nov; 62(11):1792-800. PubMed ID: 18699842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis.
    Yang N; Wu Q; Xu F; Zhang X
    J Int Med Res; 2021 Sep; 49(9):3000605211042994. PubMed ID: 34510960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis.
    Vouri SM; Kebodeaux CD; Stranges PM; Teshome BF
    Arch Gerontol Geriatr; 2017; 69():77-96. PubMed ID: 27889591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach.
    Kessler TM; Bachmann LM; Minder C; Löhrer D; Umbehr M; Schünemann HJ; Kessels AG
    PLoS One; 2011 Feb; 6(2):e16718. PubMed ID: 21373193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
    Cardozo L; Thorpe A; Warner J; Sidhu M
    BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients.
    Pagoria D; O'Connor RC; Guralnick ML
    Curr Urol Rep; 2011 Oct; 12(5):351-7. PubMed ID: 21607875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
    Cetinel B; Onal B; Gultekin MH; Guzelsoy M; Turegun FA; Dincer M
    Int Urol Nephrol; 2019 Mar; 51(3):417-424. PubMed ID: 30725387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older.
    Wagg A; Arumi D; Herschorn S; Angulo Cuesta J; Haab F; Ntanios F; Carlsson M; Oelke M
    Age Ageing; 2017 Jul; 46(4):620-626. PubMed ID: 28057620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trospium chloride treatment of overactive bladder.
    Biastre K; Burnakis T
    Ann Pharmacother; 2009 Feb; 43(2):283-95. PubMed ID: 19193592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment.
    Maruyama S; Tsukada H; Nishiyama S; Kakiuchi T; Fukumoto D; Oku N; Yamada S
    J Pharmacol Exp Ther; 2008 Jun; 325(3):774-81. PubMed ID: 18326811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study.
    Arana A; Margulis AV; McQuay LJ; Ziemiecki R; Bartsch JL; Rothman KJ; Franks B; D'Silva M; Appenteng K; Varas-Lorenzo C; Perez-Gutthann S
    Pharmacotherapy; 2018 Jun; 38(6):628-637. PubMed ID: 29723926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses.
    Buser N; Ivic S; Kessler TM; Kessels AG; Bachmann LM
    Eur Urol; 2012 Dec; 62(6):1040-60. PubMed ID: 22999811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.